TUCSON, Ariz., June 18, 2025 — Critical Path Institute’s® (C-Path) Translational Therapeutics Accelerator (TRxA) proudly announced today a $250,000 grant award aimed at developing a novel treatment ...

Global initiative to scale advanced therapeutic treatments to accelerate patient access worldwide. TUCSON, Ariz. and AMSTERDAM, March 26, 2026 /PRNewswire/ -- Critical Path Institute® (C-Path) today ...

Tucson's Critical Path Institute recently got some good news - and some noteworthy recognition - when the U.S. Senate gave final approval to a budget reauthorization bill including the Food and Drug ...

Critical Path Institute’s Translational Therapeutics Accelerator has invested in the development of QED-203 for advanced and therapy-resistant prostate cancer. Based on research at the University of ...

The Tucson-based Critical Path Institute was founded in 2005 as a public-private partnership with the U.S. Food and Drug Administration. Its main goal is to improve the drug-development process so ...

University of Virginia School of Medicine scientists have developed a bold new approach to drug development and discovery ...